RiverVest Venture Partners related stories
All articles and analysis
IPO Profile: Otonomy IncAvalon, Domain and other investors sa a 40.8x return, at the time of the IPO
Tryton Medical raises $20 mlnTryton Medical said Monday it closed $20 million in PE financing from existing investors RiverVest Venture Partners and 3x5 Special Opportunity Fund. New investor Canepa Advanced Healthcare Fund and an unnamed investor also participated. Durham, N.C.-based Tryton develops stents that are designed to treat coronary bifurcation lesions.
- VC-backed Otonomy raises $100 mln for IPO
Otonomy, a portfolio company of RiverVest Venture Partners, has launched its IPO after pricing its 6.25 million shares at $16 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol "OTIC." Based in San Diego, Otonomy is a biopharmaceutical firm that is developing treatments for the inner and middle ear.
- VC-backed Otonomy files for IPO
Otonomy said Monday that it has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be set. J.P. Morgan Securities and BofA Merrill Lynch are serving as the lead underwriters. Based in San Diego, Calif., Otonomy is a biopharmaceutical company that develops treatments for ear disorders and diseases. Its backers include Perceptive Advisors, Federated Kaufmann Funds, OrbiMed Advisors, Novo Ventures, TPG Biotech, Avalon Ventures, Domain Associates, RiverVest Venture Partners, Aperture Venture Partners and Osage University Partners.
- IPO Profile: ZS Pharma Inc
Investors, including RiverVest, Alta, Novo A/S and others, saw a 3.19x return on their $96 million investemnt
- Shire acquires VC-backed Lumena Pharmaceuticals
Shire has acquired Lumena Pharmaceuticals. No financial terms were disclosed. Citi provided financial advice to Lumena. Based in San Diego, Lumena is a biopharmaceutical company focused on rare cholestatic liver diseases and serious metabolic disorders. Its backers include New Enterprise Associates, Adage Capital Management, RA Capital Management, Pappas Ventures, RiverVest Venture Partners and Alta Partners.
VCs on the moveGeneral Catalyst adds XIR; Earlybird promotes Guericke; and Drive adds another partner
- Otonomy scores $49 mln Series D funds
Otonomy said Wednesday that it has closed $49 million in Series D funding. The investors included Perceptive Advisors, Federated Kaufmann Funds, OrbiMed Advisors, Novo Ventures, TPG Biotech, Avalon Ventures, Domain Associates, RiverVest Venture Partners, Aperture Venture Partners and Osage University Partners. Based in San Diego, Calif., Otonomy is a biopharmaceutical company that develops treatments for ear disorders and diseases.
- RiverVest promotes one and hires another
RiverVest Venture Partners said Wednesday that it has promoted Dr. Niall O’Donnell from principal to managing director. The firm has also hired Mike Berman as venture partner. Prior to joining RiverVest, O'Donnell worked at Johnson & Johnson pharmaceutical research and development in San Diego while Berman is a co-founder of eight medical technology companies including Velocimed, a RiverVest portfolio company that was bought by St. Jude Medical.
- Lumena attracts $45 mln in Series B funds
Lumena Pharmaceuticals said Tuesday that it has closed $45 million in Series B financing. New Enterprise Associates led the round with participation from Adage Capital Management, RA Capital Management, Pappas Ventures, RiverVest Venture Partners and Alta Partners. Based in San Diego, Lumena is a biopharmaceutical company focused on rare cholestatic liver diseases and serious metabolic disorders.